Alpelisib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Alpelisib. Educational only — not medical advice.
Labeled uses
VIJOICE is indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Source: FDA labeling via NIH DailyMed (set 638069a4…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.